The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Regeneron advances Eylea HD for retinal vein occlusion amid rising competition
Regeneron's Eylea HD has demonstrated noninferior visual acuity gains compared to the original Eylea in patients with macular edema following retinal vein occlusion, paving the way for a 2025 FDA filing. The drug, which generated $392 million in U.S. sales in Q3, faces competition from Amgen's biosimilar and Roche's Vabysmo, but its potential approval in RVO could boost sales further.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.